Which has better earnings & valuation, MBX or DSGN?

MBX Biosciences is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is MBX or DSGN more profitable?

MBX Biosciences' return on equity of -24.52% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Design Therapeutics N/A -33.07% -31.29%

Does the media prefer MBX or DSGN?

In the previous week, MBX Biosciences had 9 more articles in the media than Design Therapeutics. MarketBeat recorded 12 mentions for MBX Biosciences and 3 mentions for Design Therapeutics. MBX Biosciences' average media sentiment score of 0.92 beat Design Therapeutics' score of 0.76 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DSGN or MOR?

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 37.27%. Given Design Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Design Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, IRON or DSGN?

Disc Medicine is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.62 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is IRON or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% Design Therapeutics N/A -33.07% -31.29%

Does the media prefer IRON or DSGN?

In the previous week, Disc Medicine had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Disc Medicine and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.76 beat Disc Medicine's score of 0.52 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DSGN or RARE?

In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Design Therapeutics. MarketBeat recorded 13 mentions for Ultragenyx Pharmaceutical and 3 mentions for Design Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.77 beat Design Therapeutics' score of 0.76 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DSGN or BEAM?

In the previous week, Beam Therapeutics had 5 more articles in the media than Design Therapeutics. MarketBeat recorded 8 mentions for Beam Therapeutics and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.76 beat Beam Therapeutics' score of 0.70 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Design Therapeutics (DSGN) Competitors

$12.02 +0.15 (+1.26%)

Closing price 07/29/2026 04:00 PM Eastern

Extended Trading

$12.02 0.00 (-0.04%)

As of 07/29/2026 07:34 PM Eastern

Compare

DSGN vs. MBX, MOR, IRON, RARE, and BEAM

Should you buy Design Therapeutics stock or one of its competitors? MarketBeat compares Design Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Design Therapeutics include MBX Biosciences (MBX), MorphoSys (MOR), Disc Medicine (IRON), Ultragenyx Pharmaceutical (RARE), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

How does Design Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Design Therapeutics (NASDAQ:DSGN) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

In the previous week, MBX Biosciences had 9 more articles in the media than Design Therapeutics. MarketBeat recorded 12 mentions for MBX Biosciences and 3 mentions for Design Therapeutics. MBX Biosciences' average media sentiment score of 0.92 beat Design Therapeutics' score of 0.76 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences currently has a consensus target price of $71.13, indicating a potential upside of 11.20%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 37.27%. Given Design Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Design Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

MBX Biosciences' return on equity of -24.52% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Design Therapeutics	N/A	-33.07%	-31.29%

56.6% of Design Therapeutics shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MBX Biosciences has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

MBX Biosciences is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Summary

Design Therapeutics beats MBX Biosciences on 7 of the 13 factors compared between the two stocks.

How does Design Therapeutics compare to MorphoSys?

Design Therapeutics (NASDAQ:DSGN) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

Design Therapeutics has higher earnings, but lower revenue than MorphoSys. Design Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 37.27%. Given Design Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Design Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Design Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Design Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Design Therapeutics' return on equity of -33.07% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
MorphoSys	-226.79%	-694.31%	-22.55%

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Design Therapeutics had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Design Therapeutics and 0 mentions for MorphoSys. Design Therapeutics' average media sentiment score of 0.76 beat MorphoSys' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Design Therapeutics	Positive
MorphoSys	Neutral

Summary

Design Therapeutics beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Disc Medicine had 4 more articles in the media than Design Therapeutics. MarketBeat recorded 7 mentions for Disc Medicine and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.76 beat Disc Medicine's score of 0.52 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Disc Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

Design Therapeutics' return on equity of -33.07% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Design Therapeutics	N/A	-33.07%	-31.29%

Disc Medicine currently has a consensus target price of $104.44, indicating a potential upside of 41.77%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 37.27%. Given Disc Medicine's higher probable upside, research analysts clearly believe Disc Medicine is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Disc Medicine is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Summary

Design Therapeutics beats Disc Medicine on 10 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Ultragenyx Pharmaceutical?

Design Therapeutics (NASDAQ:DSGN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Design Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Design Therapeutics' return on equity of -33.07% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Design Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Design Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Ultragenyx Pharmaceutical	$673M	3.66	-$575M	-$6.11	N/A

In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Design Therapeutics. MarketBeat recorded 13 mentions for Ultragenyx Pharmaceutical and 3 mentions for Design Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.77 beat Design Therapeutics' score of 0.76 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics currently has a consensus price target of $16.50, indicating a potential upside of 37.27%. Ultragenyx Pharmaceutical has a consensus price target of $58.41, indicating a potential upside of 133.65%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Design Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Summary

Design Therapeutics beats Ultragenyx Pharmaceutical on 8 of the 15 factors compared between the two stocks.

How does Design Therapeutics compare to Beam Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Design Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Design Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 37.27%. Beam Therapeutics has a consensus target price of $46.85, indicating a potential upside of 80.04%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Design Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Beam Therapeutics	$139.74M	19.16	-$79.99M	-$0.68	N/A

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Design Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market.

In the previous week, Beam Therapeutics had 5 more articles in the media than Design Therapeutics. MarketBeat recorded 8 mentions for Beam Therapeutics and 3 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.76 beat Beam Therapeutics' score of 0.70 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Design Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$741.36M	$3.74B	$7.08B	$12.15B
Dividend Yield	N/A	2.11%	2.65%	8.53%
P/E Ratio	-10.02	22.61	27.40	23.33
Price / Sales	N/A	301.37	521.07	86.08
Price / Cash	N/A	163.15	51.57	59.34
Price / Book	3.22	7.82	10.06	5.74
Net Income	-$69.79M	$23.81M	$3.60B	$336.32M
7 Day Performance	3.35%	-3.58%	-1.40%	-1.96%
1 Month Performance	-16.93%	-8.26%	-4.38%	-6.16%
1 Year Performance	198.26%	35.02%	20.26%	13.66%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	2.4428 of 5 stars	$12.02 +1.3%	$16.50 +37.3%	+202.0%	$741.36M	N/A	N/A	40	Upcoming Earnings
MBX MBX Biosciences	2.0341 of 5 stars	$60.28 +0.2%	$63.00 +4.5%	N/A	$2.86B	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Up
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
IRON Disc Medicine	2.0499 of 5 stars	$75.58 +1.6%	$104.44 +38.2%	+23.2%	$2.84B	N/A	N/A	30	Upcoming Earnings
RARE Ultragenyx Pharmaceutical	3.814 of 5 stars	$28.62 +0.3%	$58.41 +104.1%	-9.6%	$2.81B	$673M	N/A	1,371	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 7/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. MBX, MOR, IRON, RARE, and BEAM

How does Design Therapeutics compare to MBX Biosciences?

Summary

How does Design Therapeutics compare to MorphoSys?

Summary

How does Design Therapeutics compare to Disc Medicine?

Summary

How does Design Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Design Therapeutics compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. MBX, MOR, IRON, RARE, and BEAM

How does Design Therapeutics compare to MBX Biosciences?

Does the media prefer MBX or DSGN?

Do analysts recommend MBX or DSGN?

Is MBX or DSGN more profitable?

Do institutionals & insiders believe in MBX or DSGN?

Which has more volatility & risk, MBX or DSGN?

Which has better earnings & valuation, MBX or DSGN?

Summary

How does Design Therapeutics compare to MorphoSys?

Which has higher valuation and earnings, DSGN or MOR?

Do analysts prefer DSGN or MOR?

Which has more volatility and risk, DSGN or MOR?

Is DSGN or MOR more profitable?

Do insiders and institutionals hold more shares of DSGN or MOR?

Does the media favor DSGN or MOR?

Summary

How does Design Therapeutics compare to Disc Medicine?

Does the media prefer IRON or DSGN?

Do insiders & institutionals have more ownership in IRON or DSGN?

Which has more volatility & risk, IRON or DSGN?

Is IRON or DSGN more profitable?

Do analysts prefer IRON or DSGN?

Which has better earnings & valuation, IRON or DSGN?

Summary

How does Design Therapeutics compare to Ultragenyx Pharmaceutical?

Is DSGN or RARE more profitable?

Do insiders & institutionals believe in DSGN or RARE?

Which has stronger valuation & earnings, DSGN or RARE?

Does the media favor DSGN or RARE?

Do analysts rate DSGN or RARE?

Which has more risk & volatility, DSGN or RARE?

Summary

How does Design Therapeutics compare to Beam Therapeutics?

Is DSGN or BEAM more profitable?

Do analysts prefer DSGN or BEAM?

Which has higher valuation and earnings, DSGN or BEAM?

Do insiders & institutionals have more ownership in DSGN or BEAM?

Which has more risk and volatility, DSGN or BEAM?

Does the media favor DSGN or BEAM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools